JP2018506528A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506528A5
JP2018506528A5 JP2017540056A JP2017540056A JP2018506528A5 JP 2018506528 A5 JP2018506528 A5 JP 2018506528A5 JP 2017540056 A JP2017540056 A JP 2017540056A JP 2017540056 A JP2017540056 A JP 2017540056A JP 2018506528 A5 JP2018506528 A5 JP 2018506528A5
Authority
JP
Japan
Prior art keywords
individual
osm
optionally
osmr
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017540056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506528A (ja
JP6999417B2 (ja
Filing date
Publication date
Priority claimed from GBGB1501480.6A external-priority patent/GB201501480D0/en
Priority claimed from GB201501511A external-priority patent/GB201501511D0/en
Priority claimed from GBGB1521446.3A external-priority patent/GB201521446D0/en
Application filed filed Critical
Priority claimed from PCT/GB2016/050185 external-priority patent/WO2016120625A1/en
Publication of JP2018506528A publication Critical patent/JP2018506528A/ja
Publication of JP2018506528A5 publication Critical patent/JP2018506528A5/ja
Application granted granted Critical
Publication of JP6999417B2 publication Critical patent/JP6999417B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017540056A 2015-01-29 2016-01-28 Ｉｂｄにおける治療標的及びバイオマーカー Active JP6999417B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1501480.6A GB201501480D0 (en) 2015-01-29 2015-01-29 Biomarker
GB201501511A GB201501511D0 (en) 2015-01-29 2015-01-29 Biomarker
GB1501511.8 2015-01-29
GB1501480.6 2015-01-29
GBGB1521446.3A GB201521446D0 (en) 2015-12-04 2015-12-04 Biomarker
GB1521446.3 2015-12-04
PCT/GB2016/050185 WO2016120625A1 (en) 2015-01-29 2016-01-28 Biomarker

Publications (3)

Publication Number Publication Date
JP2018506528A JP2018506528A (ja) 2018-03-08
JP2018506528A5 true JP2018506528A5 (enExample) 2019-03-07
JP6999417B2 JP6999417B2 (ja) 2022-02-04

Family

ID=55299667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540056A Active JP6999417B2 (ja) 2015-01-29 2016-01-28 Ｉｂｄにおける治療標的及びバイオマーカー

Country Status (8)

Country Link
US (1) US10822406B2 (enExample)
EP (2) EP3250599B1 (enExample)
JP (1) JP6999417B2 (enExample)
KR (1) KR20170132143A (enExample)
CN (1) CN107530431B (enExample)
AU (1) AU2016210996B2 (enExample)
MX (1) MX2017009695A (enExample)
WO (1) WO2016120625A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
JP2021522241A (ja) * 2018-04-25 2021-08-30 キニクサ ファーマシューティカルズ， リミテッド 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療
US11779643B2 (en) * 2019-08-28 2023-10-10 Children's Hospital Medical Center Methods and compositions for the treatment of an inflammatory bowel disease
JP7620324B2 (ja) * 2019-08-29 2025-01-23 国立大学法人東北大学 炎症性腸疾患の診断方法、診断プローブ及び診断キット
CN113699187B (zh) * 2020-05-20 2023-08-08 中国科学院微生物研究所 一种肠易激综合征小鼠模型及其应用
KR20230092978A (ko) 2020-10-19 2023-06-26 조에티스 서비시즈 엘엘씨 개 및 고양이 온코스타틴 m 수용체 베타에 대한 항체 및 이의 용도
IL285031A (en) * 2021-07-21 2023-02-01 Yeda Res & Dev Diagnosis of inflammatory bowel diseases
CN116377048B (zh) * 2022-04-22 2024-05-07 广州市妇女儿童医疗中心 S100a8/a9复合体在诊治先天性巨结肠中的应用
WO2025049876A1 (en) * 2023-09-01 2025-03-06 Genentech, Inc. Methods for treating inflammatory bowel disease
WO2025153079A1 (en) * 2024-01-19 2025-07-24 Biomap (Suzhou) Intelligent Technology Limited Method of treatment
CN119955922A (zh) * 2025-01-15 2025-05-09 浙江大学 生物标志物在制备炎症性肠病筛查或亚型检测产品的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693130B2 (en) 1999-02-18 2004-02-17 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6531506B1 (en) 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US5958442A (en) 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US7572896B2 (en) 2005-02-03 2009-08-11 Raven Biotechnologies, Inc. Antibodies to oncostatin M receptor
WO2007143231A2 (en) * 2006-01-10 2007-12-13 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
EP1904050B1 (en) 2005-06-06 2012-11-14 The Regents of The University of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
US20080293582A1 (en) 2006-08-30 2008-11-27 Xilin Li Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel
WO2008028044A2 (en) 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel
WO2010044952A2 (en) 2008-08-25 2010-04-22 Centocor Ortho Biotech Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
CN103209731A (zh) 2010-09-30 2013-07-17 赢创有限公司 药物输送刀片及用于将药物储仓输送到目标部位的方法
PH12013500703A1 (en) 2010-10-13 2013-05-20 Janssen Biotech Inc Human oncostatin m antibodies and methods of use
PL2643352T3 (pl) * 2010-11-23 2018-10-31 Glaxo Group Limited Białka wiążące antygen wiążące onkostatynę M (OSM)
WO2013168829A1 (en) 2012-05-11 2013-11-14 Wakayama Medical University Anti oncostatin m receptor beta antibody
BR112015028338A2 (pt) 2013-05-17 2017-07-25 Genentech Inc métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal
TR201815608T4 (tr) 2013-05-30 2018-11-21 Kiniksa Pharmaceuticals Ltd Onkastatin m reseptörü antijeni bağlayıcı proteinler.

Similar Documents

Publication Publication Date Title
JP2018506528A5 (enExample)
Liu et al. Inflammatory bowel disease biomarkers
Panes et al. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases
Cheung et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Curtis et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity
Baba et al. Survival prediction for advanced cancer patients in the real world: A comparison of the Palliative Prognostic Score, Delirium-Palliative Prognostic Score, Palliative Prognostic Index and modified Prognosis in Palliative Care Study predictor model
Papay et al. Optimising monitoring in the management of Crohn's disease: a physician's perspective
Atreya et al. Biomarkers for personalizing IBD therapy: the quest continues
CN113348254A (zh) 用于确定针对癌症患者的治疗的方法
Spassova et al. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
ES3041639T3 (en) Biomarkers and methods for assessing psoriatic arthritis disease activity
Niki et al. Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy
Oikonomopoulos et al. Identification of circulating microRNA signatures in Crohn's disease using the Nanostring nCounter technology
Inal et al. May neutrophil-lymphocyte and platelet-lymphocyte ratios indicate disease activity in ankylosing spondylitis?
Gu et al. Identification of RGS1 as a candidate biomarker for undifferentiated spondylarthritis by genome‐wide expression profiling and real‐time polymerase chain reaction
JP2018504584A (ja) 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法
Lin et al. Understanding anti‐TNF treatment failure: does serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predict therapeutic outcome to anti‐TNF therapies in biologic‐naïve patients with active luminal Crohn's disease?
Chaemsupaphan et al. Comprehensive care of ulcerative colitis: new treatment strategies
US11199534B2 (en) Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
Shimoyama et al. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study
Chernoff et al. Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores
Sudhakar et al. DOP79 Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLLIBRI consortium
Zheng et al. Platelet-to-lymphocyte percentage ratio for assessing disease activity and predicting therapeutic outcomes in ulcerative colitis
KR20200069333A (ko) 베돌리주맙 치료를 모니터링하는 방법
Plattner et al. IBDome: An integrated molecular, histopathological, and clinical atlas of inflammatory bowel diseases